Several other studies have shown how fibrate therapy can potentially cause harm, like adverse kidney events and blood clots, or even liver injury and hospitalization when used concurrently with a ...

We identified 1,116,805 statin and/or fibrate initiators who met eligibility criteria from January 1, 1998, through December 31, 2007. Of these, 86.6% were statin initiators, 12.9% were fibrate ...

Niacin (nicotinic acid) is used to prevent and treat niacin deficiency (pellagra). Bezafibrate (marketed as Bezalip and various other brand names) is a fibrate drug used as a lipid-lowering agent to ...

SIADH (syndrome of inappropriate antidiuretic hormone secretion) leads to hyponatremia water retention in hospitalized or ...

Dyslipidemia is one of the major risk factors for cardiovascular disease in diabetes mellitus. The characteristic features of diabetic dyslipidemia are a high plasma triglyceride concentration ...

Background: The incidence of hospitalized rhabdomyolysis is not well characterized among patients taking statin-fibrate combination therapies. OBJECTIVE: To estimate and compare the rates of ...